University of Pennsylvania, Department of Medicine, Division of Hematology and Oncology, Philadelphia, PA 19104, USA.
University of Pennsylvania, Department of Medicine, Division of Hematology and Oncology, Philadelphia, PA 19104, USA.
Cell Rep Med. 2022 Jun 21;3(6):100668. doi: 10.1016/j.xcrm.2022.100668.
In DESTINY-Breast 03, Trastuzumab Deruxtecan, a HER2-specific antibody-drug conjugate, proved superior to T-DM1 in patients with HER2+ metastatic breast cancer progressing on taxane and trastuzumab. This study supported its recent approval as second-line therapy in HER2+ metastatic breast cancer.
在 DESTINY-Breast 03 研究中，曲妥珠单抗-美坦新偶联物（一种 HER2 特异性抗体药物偶联物）在接受过紫杉烷和曲妥珠单抗治疗后疾病进展的 HER2+转移性乳腺癌患者中优于 T-DM1。该研究支持其最近被批准用于 HER2+转移性乳腺癌的二线治疗。
